CD274 and neoplasm: Although PD-L1 is expressed in tumor and immune cells, the biomarker is usually assessed by single chromogenic immunohistochemistry in tumor tissues, and a higher tumor proportion score (percentage of tumor cells with complete circumferential or partial membrane expression of PD-L1) is associated with a better response to ICIs [41].